
Richard (Rick) JaeBong Lee, MD, PhD, discusses choosing among the antidrogens available in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Your AI-Trained Oncology Knowledge Connection!


Published: April 29th 2020 | Updated: